• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Erosive pustular dermatosis of the scalp in a patient commenced on a bispecific antibody targeting epidermal growth factor receptor and mesenchymal-epithelial transition factor

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Rutkowski, D.
    Huddar, Prerana
    Krebs, Matthew G
    Harries, M.
    Affiliation
    Northern Care Alliance NHS Foundation Trust, Salford, UK
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    The use of targeted treatments in oncology has resulted in an increasing number of ‘on-target but off-tissue’ adverse effects. Skin reactions are common and likely represent an inhibition of pathways that have important roles in epithelial and appendageal homeostasis. We present a case of erosive pustular dermatosis of the scalp (EPD) in a patient commenced on a novel bispecific monoclonal antibody (mAB), targeting epidermal growth factor receptor (EGFR) and receptor tyrosine kinase mesenchymal–epithelial transition factor (c-MET). Although monotherapy inhibitors of c-MET are not commonly associated with cutaneous toxicities, inhibitors of EGFR are frequently characterized by a dense inflammatory infiltrate targeting the infundibulum and isthmus of the hair follicle resulting in a suppurative folliculitis, considered to be a class effect of EGFR inhibition. Interestingly, with EGFR inhibitors the presence of a severe folliculitis has been shown to be a biomarker of treatment response, and both folliculitis decalvans and EPD have been described. As far as we are aware, this is the first case of EPD reported in the literature following treatment with a mAB targeting both EGFR and c-MET. Our patient is a 77-year-old woman with metastatic lung cancer who was started on an intravenous infusion of a bispecific mAB against EGFR and c-MET in May 2019. Within the first two cycles, she developed a grade 1 folliculitis affecting her face, chest, back and extending to the scalp. The reaction was mild and responded to mildly potent topical steroids and oral lymecycline. However, in April 2021, she developed widespread erosions on the scalp with overlying exudate and crust. Following referral to dermatology, a biopsy was performed, which demonstrated an ulcerating reaction pattern, with a mixed inflammatory infiltrate composed of neutrophils, plasma cells and distorted follicles with polytrichia but negative immunofluorescence. A clinicopathological diagnosis of EPD was made. Subsequently, treatment was interrupted and dermatological treatments instigated, including Hydromol ointment and daily dressings to soften and lift the crust, and super-potent topical steroids, which were switched to tacrolimus ointment following an improvement. The patient was left with residual scarring alopecia. This case highlights the profound follicular reactions that may occur following targeted treatments in oncology, particularly those agents targeting the EGFR pathway. Collaborative multidisciplinary management is required to unravel the critical roles these mechanisms play in follicular and epithelial homeostasis, while allowing the development of effective skin-management strategies for these growing array of novel therapies.
    Citation
    Rutkowski D, Huddar P, Krebs M, Harries M. Erosive pustular dermatosis of the scalp in a patient commenced on a bispecific antibody targeting epidermal growth factor receptor and mesenchymal-epithelial transition factor. British Journal of Dermatology. 2022 Jul;187:102-3. PubMed PMID: WOS:000821831700175.
    Journal
    British Journal of Dermatology
    URI
    http://hdl.handle.net/10541/625519
    DOI
    10.1111/bjd.21343
    Additional Links
    https://dx.doi.org/10.1111/bjd.21343
    Type
    Meetings and Proceedings
    ae974a485f413a2113503eed53cd6c53
    10.1111/bjd.21343
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.